Methazolamide Extended Release Formulation via High Molecular Weight Binder
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current extended-release methazolamide formulations fail to provide a sustained release profile over 24 hours, leading to inadequate once-daily dosing for ocular conditions like glaucoma due to inconsistent drug release and handling properties, such as compressibility and friability issues.
Innovation Solution
A unique formulation combining specific methazolamide particle sizes with increased excipient viscosity and percentage, utilizing a high molecular weight binder like hydroxypropyl methylcellulose, to achieve a controlled release profile that releases 50-80% of the drug at 12 hours and 90% or greater at 24 hours, suitable for once-daily oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If extended release formulation techniques are used to maintain therapeutic serum levels, then duration of action is improved, but manufacturing precision deteriorates due to inconsistent drug release profiles and handling properties
Solution Approach 1:
The patent applies parameter changes by systematically varying critical formulation parameters including binder molecular weight (using high molecular weight binders like HPMC with viscosity ≥100,000 cP), excipient percentages, particle size distributions, and compression forces to achieve the desired 24-hour release profile while maintaining adequate handling properties. This is evident in the detailed formulation specifications and optimization processes described.
Solution Approach 2:
The patent employs composite materials by combining methazolamide with a specific matrix of excipients including high molecular weight binders (hydroxypropyl methylcellulose), fillers (lactose, microcrystalline cellulose), and lubricants (magnesium stearate) in optimized ratios. This composite approach creates a formulation that simultaneously achieves sustained release and adequate compressibility/friability characteristics.
2Ease of operation
If extended release formulation is developed to reduce dosing frequency, then ease of operation is improved, but reliability deteriorates due to inadequate handling properties and compressibility
Solution Approach 1:
The patent uses parameter changes to optimize compression force parameters and binder viscosity parameters to achieve adequate tablet hardness and low friability while maintaining the extended release profile. The specification of high molecular weight binders with specific viscosity ranges and optimized compression parameters demonstrates this approach.
Solution Approach 2:
The patent applies local quality by optimizing the distribution and properties of excipients in different regions of the tablet formulation. Specifically, the use of high molecular weight binders provides localized structural support and controlled release properties, while fillers and lubricants are distributed to ensure adequate compressibility and surface properties for handling.
3Duration of action of moving object
If high molecular weight binder with increased viscosity is used to achieve controlled release, then duration of action is improved, but device complexity increases due to formulation complexity
Solution Approach 1:
The patent applies universality by selecting high molecular weight binders like hydroxypropyl methylcellulose that perform multiple functions simultaneously: providing structural matrix for controlled release, ensuring adequate tablet hardness, controlling friability, and facilitating compression. This multi-functional approach reduces the need for additional separate excipients and simplifies the overall formulation despite the complexity of achieving 24-hour release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures sustained therapeutic effectiveness by maintaining therapeutic serum levels of methazolamide for 24 hours, enhancing patient compliance through reduced dosing frequency and improving handling properties for effective once-daily dosing.
Implementation Method 1
a high molecular weight binder, wherein the dosage form provides an in vitro release of from about 50% to about 80% by weight of the drug at 12 hours
Implementation Method 2
The formulations exhibit sustained-release properties adequate to provide therapeutic effectiveness when administered orally not more than once daily
Data Source
AI summary
A once-a-day controlled release oral dosage form of methazolamide is provided. The dosage form comprises a therapeutically effective amount of methazolamide and a high molecular weight binder. The dosage is configured for once-daily administration to a subject in need thereof, and releases methazolamide over a period of about twenty-four hours.